Lupin Limited, a global pharmaceutical major based in Mumbai, has announced a big step in strengthening its specialty business. The company’s Dutch subsidiary, Nanomi B.V., has signed a definitive agreement to acquire VISUfarma B.V., a specialty pharma company focused on eye care, for an enterprise value of €190 million.
What is VISUfarma?
VISUfarma, headquartered in Amsterdam, operates across major European countries including Italy, the UK, Spain, Germany, and France. The company specializes in ophthalmology (eye care), offering over 60 branded products for conditions like:
- Dry eye
- Glaucoma
- Eyelid hygiene & blepharitis
- Retinal health
- Nutraceuticals prescribed by ophthalmologists
In 2024, VISUfarma reported revenues of €48.1 million and has been steadily growing across Europe.
Why Lupin is Acquiring VISUfarma
Lupin said this deal is part of its strategy to expand its footprint in Europe and build a strong specialty business in ophthalmology. With VISUfarma’s established operations, Lupin gains:
- A direct presence in Europe’s largest markets
- A ready-made portfolio of innovative eye health products
- Opportunities to bring its U.S. and Mexico ophthalmology products into Europe
- A platform for expansion into other regions like Southeast Asia
Strategic Impact
- The acquisition will be funded entirely through Lupin’s existing cash reserves.
- It is expected to be completed by the end of 2025, subject to regulatory approvals in Germany and Spain.
- Lupin expects the deal to be immediately accretive—boosting both sales and profit margins.
Leadership Comments
Vinita Gupta, CEO of Lupin, said:
“We are delighted to welcome VISUfarma into the Lupin family. This acquisition strengthens our commitment to delivering innovative medicines, broadens our presence in Europe, and builds our specialty franchise in ophthalmology.”
On the other side, VISUfarma’s team sees this as a chance to grow further. Paolo Cioccetti, CEO Italy at VISUfarma, said:
“Combining with Lupin represents an exciting new chapter for VISUfarma. Together, we will work to advance eye care and improve patient outcomes globally.”
The Bigger Picture
The global ophthalmology market is valued at around €28 billion and is growing by about 6% per year. This growth is being driven by:
- An aging population
- More diabetes-related eye conditions
- Rising awareness of preventive eye care
By acquiring VISUfarma, Lupin positions itself strongly in this growing market, creating a foundation for long-term global expansion.
Leave a Reply